+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa



Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa



Infection Control and Hospital Epidemiology 30(8): 746-752



To determine risk factors and outcomes for patients with meropenem high-level-resistant Pseudomonas aeruginosa (MRPA) (minimum inhibitory concentration [MIC] > or = 32 microg/mL). Case-control-control. An 867-bed urban, teaching hospital. Fifty-eight MRPA case patients identified from an earlier P. aeruginosa study; 125 randomly selected control patients with meropenem-susceptible P. aeruginosa (MSPA) (MIC < or = 4 microg/mL), and 57 control patients without P. aeruginosa (sampled by case date/location). Patient data, outcomes, and costs were obtained via administrative database. Cases were compared to each control group while controlling for time at risk (days between admission and culture, or entire length of stay [LOS] for patients without P. aeruginosa). A multivariable model predicted risks for MRPA versus MSPA (odds ratio [95% confidence interval]): more admissions (in the prior 12 months) (1.41 [1.15, 1.74]), congestive heart failure (2.19 [1.03, 4.68]), and Foley catheter (2.53 [1.18, 5.45]) (adj. R(2) = 0.28). For MRPA versus no P. aeruginosa, risks were age (in 5-year increments) (1.17 [1.03, 1.33]), more prior admissions (1.40 [1.08, 1.81]), and more days in the intensive care unit (1.10 [1.03, 1.18]) (adj. R(2) = 0.32). Other invasive devices (including mechanical ventilation) and previous antibiotic use (including carbapenems) were nonsignificant. MRPA mortality (31%) did not differ from that of MSPA (15%) when adjusted for time at risk (P = .15) but did from mortality without P. aeruginosa (9%) (P = .01). Median LOS and costs were greater for MRPA patients versus MSPA patients and patients without P. aeruginosa: 30 days versus 16 and 10 (P<.01) and $88,425 versus $28,620 and $22,605 (P<.01). Although antibiotic use has been shown to promote resistance, our data found that prior antibiotic use was not associated with MRPA acquisition. However, admission frequency and Foley catheters were, suggesting that infection control measures are essential to reducing MRPA transmission.

(PDF emailed within 0-6 h: $19.90)

Accession: 055579248

Download citation: RISBibTeXText

PMID: 19583513

DOI: 10.1086/603527


Related references

Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa. Journal of Hospital Infection 83(2): 153-155, 2013

Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and ChemoTherapy 61(1): -, 2016

Risk factors associated with the isolation of fluoroquinolone resistant Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35(0): 49, 1995

Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. Journal of Antimicrobial ChemoTherapy 55(4): 535-541, 2005

Multidrug-Resistant Pseudomonas aeruginosa Keratitis: Risk Factors, Clinical Characteristics, and Outcomes. Ophthalmology 122(10): 2110-2114, 2015

Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes. Clinical Microbiology and Infection 12(1): 63-68, 2006

Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. Journal of Hospital Infection 57(2): 112-118, 2004

Risk factors and clinical outcomes of nosocomial infections caused by multidrug resistant Pseudomonas aeruginosa. Zhonghua Jie He He Hu Xi Za Zhi 27(1): 31-35, 2004

Multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii infections among hospitalized patients: risk factors and outcomes. Journal of the Association of Physicians of India 57(): 636, 638-640, 645, 2010

Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections. Infection 42(4): 721-728, 2015

Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. Journal of Critical Care 23(1): 18-26, 2008

Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. Journal of Hospital Infection 64(1): 7-15, 2006

Comparative in vitro activity of meropenem against pseudomonas aeruginosa and pseudomonas maltophilia isolated from cystic fibrosis patients including imipenem resistant strains. Abstracts of the General Meeting of the American Society for Microbiology 91: 3, 1991

In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa. Journal of ChemoTherapy 8(5): 358-364, 1996

Antipseudomonal activity of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 34(0): 30, 1994